Influencing Factors on Independent Walking in Children With Lumbosacral Lipomas: A Retrospective Cohort Study Based on a 5-Year Untethering Series

Chiaki Takeuchi¹, Shiro Sugiura², Remi Fujita³, Noriatsu Tatematsu⁴ and Hideshi Sugiura⁴

¹Rehabilitation Section, Clinical Support Division, Aichi Children's Health and Medical Canter, Obu, Aichi, Japan. ²Department of Maternal and Child Health, Aichi Children's Health and Medical Center, Obu, Aichi, Japan. ³Faculty of Rehabilitation and Care, Seijoh University, Tokai, Aichi, Japan. ⁴Department of Integrated Health Sciences, Nagoya University Graduate School of Medicine, Higashi-ku, Nagoya, Aichi, Japan.

ABSTRACT

BACKGROUND: Caregivers are deeply concerned about children achieving independent walking, and evidence-based rehabilitation support is beneficial. However, current research is confined to a single study on spina bifida aperta, leaving a gap in understanding the timing of independent walking for lumbosacral lipomas.

OBJECTIVES: This study aimed to examine the factors influencing independent walking in children with lumbosacral lipomas.

DESIGN: Retrospective cohort study.

METHODS: This retrospective cohort study included 124 children who underwent untethering surgery for lumbosacral lipomas. The age (in months) at which the children walked independently was used as the primary endpoint, and potential influencing factors, including the type of spinal lipoma, extent of lipoma removal, magnetic resonance imaging features, congenital anomaly complications, urinary/defecation management requirements, foot/toe symptoms, and orthotic device fabrications were analyzed.

RESULTS: Multiple logistic regression analysis showed that the most significant influencing factor for delayed independent walking was the presence of systemic combined anomalies (adjusted odds ratio = 15.5, P < .001), while non-systemic malformations, such as suburethral cleft, had limited effects. A subgroup analysis of 94 patients without systemic combined anomalies showed that the presence of a malformed conus medullaris was significantly associated with delayed independent walking (P = .014). The median age of independent walking in children with Morota's classification type 2 was 14 months, which is 1 month later compared to other types, although this difference was not significant (P = .055).

CONCLUSION: Our findings suggest that complications arising from systemic combined anomalies and the presence of malformed conus medullaris are influencing factors in delays in independent walking in children with untethered lumbosacral lipomas.

KEYWORDS: Spina bifida occulta, neurulation failure, congenital malformation, conus medullaris malformation, motor developmental milestone, pediatric rehabilitation

RECEIVED: November 10, 2023, ACCEPTED: August 21, 2024. **TYPE:** Research Article

Introduction

Spina bifida aperta has long been studied, with the site of origin and the degree of neurological impairment determining future function.¹⁻³ Recently, postoperative motor function in lumbosacral lipomas and spina bifida occulta has been widely reported, with most children achieving ambulation in early childhood.⁴ de Vloo et al⁵ reported that 56% of 91 patients with lumbosacral lipomas who underwent radical resections had normal motor function, 32% had slight muscle weakness or delayed milestones but did not require walking aids, and the remaining 12% required walking aids. Thuy et al⁶ reported that 11 of 63 patients who underwent untethering had motor weakness or gait disturbances. Koyanagi et al⁷ found motor deficits in 9 of 34 patients who underwent detethering, of whom 7 had lipomas that extended beyond the L5 level of the spine and

CORRESPONDING AUTHOR: Chiaki Takeuchi, Aichi Children's Health and Medical Canter, 7-426 Morioka, Obu, Aichi 474-8710, Japan. Email: chiaki_takeuchi@sk00106. achmc.pref.aichi.jp.

were of the transitional type, which was more likely to result in severe motor deficits. Other lumbosacral lipomas have been reported to have different neurological prognoses depending on their location and size; however, none of these studies clearly state whether independent walking can be achieved.8-15

Acquiring independent walking is a major concern of caregivers, and presenting evidence-based rehabilitation support is useful for affected children. However, recent studies on the timing of independent walking are limited to only 1 report on spina bifida apertam,¹⁶ and there is a lack of studies investigating this in lumbosacral lipomas. Therefore, we conducted a retrospective cohort study of children with untethered lumbosacral lipomas at the Aichi Children's Health and Medical Center (ACHMC) to identify factors influencing delays in acquiring independent walking.

 $(\mathbf{\hat{n}})$

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).

Clinical Medicine Insights: Pediatrics Volume 18: 1-10 © The Author(s) 2024 Article reuse guidelines: sagepub.com/journals-permissions DOI: 10.1177/11795565241281334



Methods

Recruitment of participants

This was a retrospective cohort study. The study population consisted of all children who underwent untethering surgery for lumbosacral lipomas between February 2016 and February 2021 at the ACHMC.

Exclusion criteria were (1) different pathology, (2) additional operations, (3) moved away (relocation), (4) died in infancy, and (5) lack of walking data.

Primary endpoints

The primary outcome was the age at which independent walking was achieved. The age in months was extracted from the medical records, which were transferred from the records of the maternal and child health handbook.¹⁷ The ages of preterm infants were expressed as corrected ages in months.¹⁸ Cohort entry was set at birth, and the primary follow-up concluded 1-month post-independence. Requirement of orthotic devices was not a condition for acquiring independent walking. Children unable to achieve independent walking by 60 months of age were classified as unconfirmed cases.

Based on the World Health Organization's motor development milestones¹⁹ and recent studies on normal development in Japanese children,²⁰ we divided the subjects into normal (independent walking acquired before 15 months of age), borderline (independent walking acquired between 15 and 18 months of age), and delayed (independent walking acquired after 18 months or older, including unconfirmed cases) groups.

Examination of influencing factors

Data on sex, gestational age, birthweight, small for gestational age (SGA),²¹ age at untethering (in months), timing of untethering (before or after independent walking), type of spinal lipoma, extent of lipoma removal, magnetic resonance imaging (MRI) findings (syrinx, low-set conus medullaris, and malformed conus medullaris), congenital anomaly complications, urinary and defecation management requirements, foot and toe symptoms, and orthotic device fabrications were extracted from the medical records.

The classification of spinal lipoma types followed the Morota's classification by Morota et al.²² This classification delineates types 1 to 4 based on the conus medullaris and lipoma's location using MRI features, and these types were established by 2 or more expert neurosurgeons and were confirmed through intraoperative findings. The extent of lipoma removal was categorized as "total removal," "partial removal," or "conservative untethering" (which involves untethering without lipoma removal), based on details from surgical records. For congenital anomaly complications, patients with 1 or 2 of the 4 categories of malformations—(1) anorectal anomalies such as anal atresia, (2) urogenital anomalies such as hypospadias, (3)

sacral anomalies, or (4) minor anomalies such as congenital hydronephrosis and some congenital malformations around the pelvic/perineal region—were classified as having "associated/minor malformations." Those with 3 or more malformations, including associated/minor malformations, anomaly syndromes such as VACTERL (vertebral defects, anal atresia, cardiac defects, trachea-esophageal fistula, renal abnormalities, and limb abnormalities), congenital heart diseases, congenital strabismus/amblyopia and other non-secondary syndromes with potential implications for delays in motor development, were classified as having "systemic combined anomalies."²²⁻²⁴

For urinary and defecation management, the designation "yes" applied to patients requiring drug intervention for incontinence or urinary retention, daily urinary drainage, routine hostile stool management (enema or swab stimulation), or treatment involving bisacodyl or magnesium oxide. These classifications and definitions were obtained and recorded by expert urologists after untethering. Regarding foot and toe symptoms, the label "yes" was assigned if patients exhibited any of the following descriptions: talipes valgus, varus, planus, equinus, cavus, or calcaneus, mallet toes, or an inability to spread toes. Data on foot and toe symptoms were collected after 12 months of independent walking.

Statistical analysis

Multiple logistic regression analyses were performed, with both "the normal versus borderline and delayed groups" and "normal and borderline versus delayed groups" as objective variables (binary variables) and sex, gestational age, SGA, and congenital anomaly complications (associated/minor malformations and systemic combined anomalies) as explanatory variables.

For the subgroup analysis in those without systemic combined anomalies, multiple regression analysis was performed with age of independent walking (in months) as the objective variable (continuous variable) and 6 items—sex, extent of lipoma removal, congenital anomaly complications (associated/ minor malformations), and 3 MRI findings (syrinx, low-set conus medullaris, and malformed conus medullaris) that were used as criteria for determining the Morota's classification type—as explanatory variables.

In the subgroups, comparisons based on the Morota's classification types were conducted using Fisher's exact or Kruskal-Wallis tests for each examination factor and log-rank tests for the cumulative incidence of achievement of independent walking.

All statistical analyses were performed using R ver. 4.3.0, R Commander ver. 2.8-0, and the plug-in EZR ver. 1.61 for Windows.²⁵

Post hoc power analyses for predictor analysis were conducted to verify the sample size using G*Power 3.1.9.7. ²⁶ The alpha level used for this study was P < .05.




Figure 1. Participant recruitment and inclusion criteria.

Ethics

The study was approved by the Ethics Committee of the ACHMC (approval number 2021093) and the Bioethics Committee of Nagoya University (approval number 22-501). As this was a study involving the secondary use of existing data, the requirement for individual consent was waived.

Results

Intraspinal operations for neural tube defects were performed in 165 children during the study period. Among these children, 26 had myelomeningoceles, 5 had a different pathological diagnosis of spinal lipoma, 8 had no information on when they achieved ambulation due to unrecorded data, and 2 had additional operations performed; thus, 124 children—73 in the normal, 26 in the borderline, and 25 in the delayed groups—were included (Figure 1). The patients' backgrounds and clinical characteristics are listed in Table 1. The median age at untethering was 9.9 months, and 65% of patients were untethered before independent walking. The median age of independent walking was 14 months. The acquisition status of independent walking in the included patients is shown in a histogram in Figure 2.

Factors influencing the timing of independent walking

Multiple logistic regression analyses showed that systemic combined anomaly complications were significantly associated with the age of independent walking in the delayed group, with adjusted odds ratios (OR) of 15.5 (normal vs borderline/delayed) and 43.2 (normal/borderline vs delayed) (Table 2). Sensitivity analyses were performed excluding 3 unconfirmed cases, with similar results (ORs of 13.7 and 36.7, respectively). No other items were significantly associated with the age of independent walking. The cumulative incidence of achievement of independent walking in those with congenital anomaly complications is shown in Figure 3.

The post hoc power values of the total sample size of 124 were 98%, 84%, and 71% for effect sizes assumed to be OR = 2.6, 2.0, and 1.8, respectively. Thus, ORs of 2.6 and over for logistic regression analysis in this study were valid to detect statistically significant differences.

Subgroup analyses were performed on 94 cases with no remarkable anomalies or associated/minor malformations. In the single regression analysis, malformed conus medullaris, urinary management, and toe symptoms were associated with

Table 1.	Characteristics	of the	study	population	(n = 1)	24).
----------	-----------------	--------	-------	------------	---------	------

Sex, male64 (52%)Gestational age (weeks)39.0 (24.0-41.9)Birthweight (g)2805 (699-4244)SGA53 (43%)Male25 (47%)Morota's classification25 (47%)Type 116 (13%)Type 224 (19%)Type 314 (11%)Type 470 (56%)Surgical procedure information81 (65%)Surgery prior to independent walking Surgery prior to independent walking81 (65%)Partial removal60 (48%)Conservative untethering30 (24%)Conservative untethering30 (24%)Others4 (3%)Associated/minor malformations26 (21%)Urogenital anomalies7 (6%)Congenital nomalies7 (6%)Congenital nomalies7 (6%)Congenital hydronephrosis5 (4%)Others4 (3%)Multiple anomalies7 (6%)Congenital hydronephrosis5 (4%)Optic anomalies30 (24%)Multiple anomalies7 (6%)Congenital hydronephrosis5 (4%)Optic anomalies3 (2%)Quito que di leson3 (2%)Quito que di leson3 (2%)Spinal cord lesion3 (2%)Quito que di leson3 (2%)Anorectal anomalies5 (4%)Optic anomalies4 (3%)Anorectal anomalies5 (4%)Optic anomalies3 (2%)Anorectal information3 (2%)Anorectal leson3 (2%)Anorectal anomalies5 (4%)	VARIABLES	VALUES
Birthweight (g)2805 (699-4244)SGA53 (43%)Male25 (47%)Morota's classification25 (47%)Type 116 (13%)Type 224 (19%)Type 314 (11%)Type 470 (56%)Surgical procedure information9.9 months (0.1 months to 14.4 years)Surgery prior to independent walking 81 (65%)81 (65%)Extent of lipoma removal60 (48%)Conservative untethering30 (24%)Conservative untethering30 (24%)No remarkable anomalies68 (55%)Anorectal anomalies7 (6%)Anorectal anomalies7 (6%)Congenital hydronephrosis5 (4%)Others4 (3%)Multiple anomalies30 (24%)Orthopedic diseases (CHD)5 (4%)Orthopedic diseases (CHD)5 (4%)Optic anomalies3 (2%)Appinal cord lesion3 (2%)21 trisomy + CHD2 (2%)Others4 (3%)Age of independent walking (months)14 (10-42)Normal group (<15 months)	Sex, male	64 (52%)
SGA 53 (43%) Male 25 (47%) Morota's classification	Gestational age (weeks)	39.0 (24.0-41.9)
Male 25 (47%) Morota's classification 24 (19%) Type 1 16 (13%) Type 2 24 (19%) Type 4 70 (56%) Surgical procedure information 30 (26%) Surgery prior to independent walking 81 (65%) Extent of lipoma removal 60 (48%) Partial removal 60 (48%) Partial removal 34 (27%) Conservative untethering 30 (24%) Congenital anomalies 68 (55%) Associated/minor malformations 26 (21%) Urogenital anomalies 7 (6%) Anorectal anomalies 7 (6%) Others 4 (3%) Systemic combined anomalies 5 (4%) Others 4 (3%) Spinal cord lesion 3 (2%) 21 trisomy + CHD 2 (2%) Others 4 (3%) Age of independent walking (months) 14 (10-42)	Birthweight (g)	2805 (699-4244)
Morota's classification Type 1 16 (13%) Type 2 24 (19%) Type 3 14 (11%) Type 4 70 (56%) Surgical procedure information 14 (11%) Age at untethering 9.9 months (0.1 months to 14.4 years) Surgery prior to independent walking 81 (65%) Extent of lipoma removal 60 (48%) Partial removal 60 (48%) Conservative untethering 30 (24%) Conservative untethering 30 (24%) Congenital anomalies 68 (55%) Associated/minor malformations 26 (21%) Urogenital anomalies 7 (6%) Anorectal anomalies 7 (6%) Congenital hydronephrosis 5 (4%) Others 4 (3%) Systemic combined anomalies 7 (6%) Others 4 (3%) Spinal cord lesion 3 (2%) Qptic anomalies 5 (4%) Optic anomalies 5 (4%) Optic anomalies 5 (4%) Optic anomalies 4 (3%) Spinal cord lesion	SGA	53 (43%)
Type 1 16 (13%) Type 2 24 (19%) Type 3 14 (11%) Type 4 70 (56%) Surgical procedure information 3.9 months (0.1 months to 14.4 years) Age at untethering 9.9 months (0.1 months to 14.4 years) Surgery prior to independent walking 81 (65%) Extent of lipoma removal 60 (48%) Partial removal 30 (24%) Congenital anomaly complications 26 (21%) Vo remarkable anomalies 68 (55%) Associated/minor matformations 26 (21%) Urogenital anomalies 7 (6%) Anorectal anomalies 7 (6%) Others 4 (3%) Systemic combined anomalies 30 (24%) Others 4 (3%) Systemic combined anomalies 5 (4%) Others 5 (4%) Optic anomalies 5 (4%) Optic anomalies 3 (2%) Spinal cord lesion 3 (2%) Spinal cord lesion 3 (2%) Aptic anomalies 4 (3%) Aptic anomalies 3 (2%) </td <td>Male</td> <td>25 (47%)</td>	Male	25 (47%)
Type 2 24 (19%) Type 3 14 (11%) Type 4 70 (56%) Surgical procedure information 9.9 months (0.1 months to 14.4 years) Age at untethering 9.9 months (0.1 months to 14.4 years) Surgery prior to independent walking 81 (65%) Extent of lipoma removal 60 (48%) Partial removal 60 (48%) Partial removal 30 (24%) Conservative untethering 30 (24%) Congenital anomaly complications 26 (21%) Vurgenital anomalies 68 (55%) Anorectal anomalies 7 (6%) Congenital nomalies 7 (6%) Congenital hydronephrosis 5 (4%) Others 4 (3%) Systemic combined anomalies 30 (24%) Multiple anomaly syndromes 7 (6%) Congenital heart disease (CHD) 5 (4%) Others 4 (3%) Spinal cord lesion 3 (2%) Qutto anomalies 3 (2%) Optic anomalies 4 (3%) Spinal cord lesion 3 (2%) Qutto anomalies <td>Morota's classification</td> <td></td>	Morota's classification	
Type 314 (11%)Type 470 (56%)Surgical procedure informationAge at untethering9.9 months (0.1 months to 14.4 years)Surgery prior to independent walking81 (65%)Extent of lipoma removal60 (48%)Partial removal34 (27%)Conservative untethering30 (24%)Congenital anomaly complications68 (55%)No remarkable anomalies68 (55%)Associated/minor malformations26 (21%)Urogenital anomalies7 (6%)Congenital anomalies7 (6%)Congenital anomalies5 (4%)Others4 (3%)Systemic combined anomalies30 (24%)Multiple anomaly syndromes7 (6%)Congenital heart disease (CHD)5 (4%)Optic anomalies3 (2%)Spinal cord lesion3 (2%)21 trisomy + CHD2 (2%)Others4 (3%)Age of independent walking (months)14 (10-42)Normal group (<15 months)	Туре 1	16 (13%)
Type 470 (56%)Surgical procedure informationAge at untethering9.9months (0.1 months to 14.4 years)Surgery prior to independent walking81 (65%)Extent of lipoma removal60 (48%)Partial removal60 (48%)Partial removal30 (24%)Conservative untethering30 (24%)Congenital anomaly complications26 (21%)No remarkable anomalies68 (55%)Associated/minor malformations26 (21%)Urogenital anomalies11 (9%)Sacral anomalies7 (6%)Anorectal anomalies5 (4%)Others4 (3%)Systemic combined anomalies30 (24%)Multiple anomaly syndromes7 (6%)Congenital heart disease (CHD)5 (4%)Optic anomalies3 (2%)21 trisomy + CHD2 (2%)Others4 (3%)Age of independent walking (months)14 (10-42)Normal group (<15months)	Туре 2	24 (19%)
Surgical procedure information Age at untethering 9.9 months (0.1 months to 14.4 years) Surgery prior to independent walking 81 (65%) Extent of lipoma removal 60 (48%) Partial removal 60 (48%) Partial removal 34 (27%) Conservative untethering 30 (24%) Congenital anomaly complications Congenital anomalies No remarkable anomalies 68 (55%) Associated/minor malformations 26 (21%) Urogenital anomalies 11 (9%) Sacral anomalies 7 (6%) Anorectal anomalies 5 (4%) Others 4 (3%) Systemic combined anomalies 30 (24%) Others 4 (3%) Optic anomalies 5 (4%) Optic anomalies 5 (4%) Optic anomalies 4 (3%) Spinal cord lesion 3 (2%) 21 trisomy + CHD 2 (2%) Others 4 (3%) Age of independent walking (months) 14 (10-42) Normal group (<15 months)	Туре 3	14 (11%)
Age at untethering9.9 months (0.1 months to 14.4 years)Surgery prior to independent walking81 (65%)Extent of lipoma removal60 (48%)Partial removal60 (48%)Partial removal34 (27%)Conservative untethering30 (24%)Congenital anomaly complications68 (55%)No remarkable anomalies68 (55%)Associated/minor malformations26 (21%)Urogenital anomalies11 (9%)Sacral anomalies7 (6%)Congenital hydronephrosis5 (4%)Others4 (3%)Systemic combined anomalies30 (24%)Multiple anomaly syndromes7 (6%)Congenital heart disease (CHD)5 (4%)Optic anomalies3 (2%)21 trisomy + CHD2 (2%)Others4 (3%)Age of independent walking (months)14 (10-42)Normal group (<15 months)	Туре 4	70 (56%)
14.4 years)Surgery prior to independent walking81 (65%)Extent of lipoma removal60 (48%)Partial removal60 (48%)Partial removal34 (27%)Conservative untethering30 (24%)Congenital anomaly complications68 (55%)Associated/minor malformations26 (21%)Urogenital anomalies11 (9%)Sacral anomalies7 (6%)Anorectal anomalies7 (6%)Congenital hydronephrosis5 (4%)Others4 (3%)Systemic combined anomalies30 (24%)Multiple anomaly syndromes7 (6%)Congenital heart disease (CHD)5 (4%)Optic anomalies3 (2%)21 trisomy + CHD2 (2%)Others4 (3%)Age of independent walking (months)14 (10-42)Normal group (<15 months)	Surgical procedure information	
Extent of lipoma removalTotal removal60 (48%)Partial removal34 (27%)Conservative untethering30 (24%)Congenital anomaly complications68 (55%)Associated/minor malformations26 (21%)Urogenital anomalies7 (6%)Anorectal anomalies7 (6%)Anorectal anomalies7 (6%)Congenital hydronephrosis5 (4%)Others4 (3%)Systemic combined anomalies30 (24%)Multiple anomaly syndromes7 (6%)Congenital heart disease (CHD)5 (4%)Optic anomalies3 (2%)Spinal cord lesion3 (2%)21 trisomy + CHD2 (2%)Others4 (3%)Age of independent walking (months)14 (10-42)Normal group (<15-18 months)	Age at untethering	
Total removal60 (48%)Partial removal34 (27%)Conservative untethering30 (24%)Congenital anomaly complicationsCongenital anomaly complicationsNo remarkable anomalies68 (55%)Associated/minor malformations26 (21%)Urogenital anomalies11 (9%)Sacral anomalies7 (6%)Anorectal anomalies7 (6%)Congenital hydronephrosis5 (4%)Others4 (3%)Systemic combined anomalies30 (24%)Multiple anomaly syndromes7 (6%)Congenital heart disease (CHD)5 (4%)Optic anomalies3 (2%)Spinal cord lesion3 (2%)21 trisomy + CHD2 (2%)Others4 (3%)Age of independent walking (months)14 (10-42)Normal group (<15 months)	Surgery prior to independent walking	81 (65%)
Partial removal34 (27%)Conservative untethering30 (24%)Congenital anomaly complicationsNo remarkable anomalies68 (55%)Associated/minor malformations26 (21%)Urogenital anomalies11 (9%)Sacral anomalies7 (6%)Anorectal anomalies7 (6%)Congenital hydronephrosis5 (4%)Others4 (3%)Systemic combined anomalies30 (24%)Multiple anomaly syndromes7 (6%)Congenital heart disease (CHD)5 (4%)Optic anomalies5 (4%)Optic anomalies3 (2%)21 trisomy + CHD2 (2%)Others4 (3%)Age of independent walking (months)14 (10-42)Normal group (<15 months)	Extent of lipoma removal	
Conservative untethering30 (24%)Congenital anomaly complicationsNo remarkable anomalies68 (55%)Associated/minor malformations26 (21%)Urogenital anomalies11 (9%)Sacral anomalies7 (6%)Anorectal anomalies7 (6%)Congenital hydronephrosis5 (4%)Others4 (3%)Systemic combined anomalies30 (24%)Multiple anomaly syndromes7 (6%)Congenital heart disease (CHD)5 (4%)Optic anomalies3 (2%)Spinal cord lesion3 (2%)21 trisomy + CHD2 (2%)Others4 (3%)Age of independent walking (months)14 (10-42)Normal group (<15 months)	Total removal	60 (48%)
Congenital anomaly complicationsNo remarkable anomalies68 (55%)Associated/minor malformations26 (21%)Urogenital anomalies11 (9%)Sacral anomalies7 (6%)Anorectal anomalies7 (6%)Congenital hydronephrosis5 (4%)Others4 (3%)Systemic combined anomalies30 (24%)Multiple anomaly syndromes7 (6%)Congenital heart disease (CHD)5 (4%)Orthopedic diseases5 (4%)Optic anomalies3 (2%)21 trisomy + CHD2 (2%)Others4 (3%)Age of independent walking (months)14 (10-42)Normal group (<15-18 months)	Partial removal	34 (27%)
No remarkable anomalies68 (55%)Associated/minor malformations26 (21%)Urogenital anomalies11 (9%)Sacral anomalies7 (6%)Anorectal anomalies7 (6%)Congenital hydronephrosis5 (4%)Others4 (3%)Systemic combined anomalies30 (24%)Multiple anomaly syndromes7 (6%)Congenital heart disease (CHD)5 (4%)Orthopedic diseases5 (4%)Optic anomalies3 (2%)21 trisomy + CHD2 (2%)Others4 (3%)Age of independent walking (months)14 (10-42)Normal group (<15 months)	Conservative untethering	30 (24%)
Associated/minor malformations26 (21%)Urogenital anomalies11 (9%)Sacral anomalies7 (6%)Anorectal anomalies7 (6%)Congenital hydronephrosis5 (4%)Others4 (3%)Systemic combined anomalies30 (24%)Multiple anomaly syndromes7 (6%)Congenital heart disease (CHD)5 (4%)Orthopedic diseases5 (4%)Optic anomalies4 (3%)Spinal cord lesion3 (2%)21 trisomy + CHD2 (2%)Others4 (3%)Age of independent walking (months)14 (10-42)Normal group (<15 months)	Congenital anomaly complications	
Urogenital anomalies11 (9%)Sacral anomalies7 (6%)Anorectal anomalies7 (6%)Congenital hydronephrosis5 (4%)Others4 (3%)Systemic combined anomalies30 (24%)Multiple anomaly syndromes7 (6%)Congenital heart disease (CHD)5 (4%)Orthopedic diseases5 (4%)Optic anomalies3 (2%)Spinal cord lesion3 (2%)21 trisomy + CHD2 (2%)Others4 (3%)Age of independent walking (months)14 (10-42)Normal group (<15 months)	No remarkable anomalies	68 (55%)
Sacral anomalies7 (6%)Anorectal anomalies7 (6%)Congenital hydronephrosis5 (4%)Others4 (3%)Systemic combined anomalies30 (24%)Multiple anomaly syndromes7 (6%)Congenital heart disease (CHD)5 (4%)Orthopedic diseases5 (4%)Optic anomalies4 (3%)Spinal cord lesion3 (2%)21 trisomy + CHD2 (2%)Others4 (3%)Age of independent walking (months)14 (10-42)Normal group (<15 months)	Associated/minor malformations	26 (21%)
Anorectal anomalies7 (6%)Congenital hydronephrosis5 (4%)Others4 (3%)Systemic combined anomalies30 (24%)Multiple anomaly syndromes7 (6%)Congenital heart disease (CHD)5 (4%)Orthopedic diseases5 (4%)Optic anomalies4 (3%)Spinal cord lesion3 (2%)21 trisomy + CHD2 (2%)Others4 (3%)Age of independent walking (months)14 (10-42)Normal group (<15 months)	Urogenital anomalies	11 (9%)
Congenital hydronephrosis5 (4%)Others4 (3%)Systemic combined anomalies30 (24%)Multiple anomaly syndromes7 (6%)Congenital heart disease (CHD)5 (4%)Orthopedic diseases5 (4%)Optic anomalies4 (3%)Spinal cord lesion3 (2%)21 trisomy + CHD2 (2%)Others4 (3%)Age of independent walking (months)14 (10-42)Normal group (<15 months)	Sacral anomalies	7 (6%)
Others4 (3%)Systemic combined anomalies30 (24%)Multiple anomaly syndromes7 (6%)Congenital heart disease (CHD)5 (4%)Orthopedic diseases5 (4%)Optic anomalies4 (3%)Spinal cord lesion3 (2%)21 trisomy + CHD2 (2%)Others4 (3%)Age of independent walking (months)14 (10-42)Normal group (<15 months)	Anorectal anomalies	7 (6%)
Systemic combined anomalies30 (24%)Multiple anomaly syndromes7 (6%)Congenital heart disease (CHD)5 (4%)Orthopedic diseases5 (4%)Optic anomalies4 (3%)Spinal cord lesion3 (2%)21 trisomy + CHD2 (2%)Others4 (3%)Age of independent walking (months)14 (10-42)Normal group (<15 months)	Congenital hydronephrosis	5 (4%)
Multiple anomaly syndromes7 (6%)Congenital heart disease (CHD)5 (4%)Orthopedic diseases5 (4%)Optic anomalies4 (3%)Spinal cord lesion3 (2%)21 trisomy + CHD2 (2%)Others4 (3%)Age of independent walking (months)14 (10-42)Normal group (<15 months)	Others	4 (3%)
Congenital heart disease (CHD)5 (4%)Orthopedic diseases5 (4%)Optic anomalies4 (3%)Spinal cord lesion3 (2%)21 trisomy + CHD2 (2%)Others4 (3%)Age of independent walking (months)14 (10-42)Normal group (<15 months)	Systemic combined anomalies	30 (24%)
Orthopedic diseases5 (4%)Optic anomalies4 (3%)Spinal cord lesion3 (2%)21 trisomy + CHD2 (2%)Others4 (3%)Age of independent walking (months)14 (10-42)Normal group (<15 months)	Multiple anomaly syndromes	7 (6%)
Optic anomalies4 (3%)Spinal cord lesion3 (2%)21 trisomy + CHD2 (2%)Others4 (3%)Age of independent walking (months)14 (10-42)Normal group (<15 months)	Congenital heart disease (CHD)	5 (4%)
Spinal cord lesion3 (2%)21 trisomy + CHD2 (2%)Others4 (3%)Age of independent walking (months)14 (10-42)Normal group (<15 months)	Orthopedic diseases	5 (4%)
21 trisomy + CHD2 (2%)Others4 (3%)Age of independent walking (months)14 (10-42)Normal group (<15 months)	Optic anomalies	4 (3%)
Others4 (3%)Age of independent walking (months)14 (10-42)Normal group (<15 months)	Spinal cord lesion	3 (2%)
Age of independent walking (months)14 (10-42)Normal group (<15 months)	21 trisomy + CHD	2 (2%)
Normal group (<15 months)73 (59%)Borderline group (15-18 months)25 (20%)	Others	4 (3%)
Borderline group (15-18 months)25 (20%)	Age of independent walking (months)	14 (10-42)
	Normal group (<15 months)	73 (59%)
Delayed group (18 months) ^a 26 (21%)	Borderline group (15-18 months)	25 (20%)
	Delayed group (18 months) ^a	26 (21%)

Abbreviations: SGA, small for gestational age.

Values represent the number of patients (%) or median (range).

^aThree children had not achieved independent walking until 60 months of age.

delayed achievement of independent walking, whereas other factors were not associated. In the multiple regression analysis, which included 6 indicators (sex, associated/minor malformations, extent of lipoma removal, and the 3 MRI findings of syrinx, low-set conus medullaris, and malformed conus medullaris), only the presence of a malformed conus medullaris was significantly associated with the delayed achievement of independent walking (Table 3).

The post hoc power values of a sample size of a subgroup of 94 with 6 predictors (independent variables) for multiple regression analysis were 99% and 78% for effect sizes assumed to be large ($f^2 = 0.35$) and medium ($f^2 = 0.15$), respectively. The number of subjects used for subgroup analysis was therefore sufficiently large to detect statistically significant differences.

Comparison according to Morota's classification types

The comparison based on Morota's classification types in the subgroups without systemic combined anomalies is presented in Table 4. Type 2 cases tended to have an earlier age at untethering surgery (significantly or marginal significantly), with all procedures conducted before the achievement of independent walking. In addition, 62% of type 2 cases presented with lipomyelomeningoceles, and this subgroup exhibited the lowest rate of total removal of lipoma at 33%.

MRI findings indicated an increased prevalence of syrinx and low-set conus medullaris in most cases compared to type 4 cases. Moreover, significant variations were observed among types in terms of urinary management, foot/toe symptoms, and orthotic device fabrications.

Comparisons were conducted among the Morota's classification types regarding the age in months for independent walking. Out of the cases, 14 belonged to type 1, 12 to type 3, and 47 to type 4, with a median age of independent walking of 13 months (ranges, 10-17, 11-15, and 10-18, respectively). Meanwhile, the 21 cases classified as type 2 achieved independent walking at a median age of 14 months (range, 11-20), which was slight later. Additionally, a delay in cumulative incidence was also observed in these cases, but this difference was not statistically significant (P=.055, Figure 4).

Discussion

The retrospective cohort study showed that the presence of systemic combined anomalies was the strongest factor associated with delayed achievement of independent walking in children with untethered lumbosacral lipomas, while the presence of a malformed conus medullaris was a possible factor. This study is the first of its kind to pinpoint potential risk factors associated with the delayed attainment of independent walking. Such findings hold valuable information for the families of patients and contribute to enhancing their understanding of the condition.




Figure 2. Histogram of achieved independent walking ages in months. The histogram is segmented into 3 distinct groups: normal, borderline, and delayed, each demarcated by dotted lines. Unconfirmed cases were included in the delayed group.

Table 2. Significant variables between normal group versus delayed/borderline group and normal/borderline group versus delayed group.

	NOMAL (N=	NOMAL (N=73) VS BORDERLINE/DELAYED (N=51)			NORMAL/BORDERLINE (N=98) VS DELAYED (N=26)			
	OR	95% CI	P VALUE	OR	95% CI	P VALUE		
Sex (female=0, male=1)	1.170	0.497-2.750	.721	2.860	0.772-10.60	.116		
Gestational age	0.963	0.823-1.130	.639	0.991	0.759-1.290	.948		
SGA	0.785	0.330-1.860	.538	1.610	0.460-5.660	.647		
Associated/minor malformations	1.920	0.661-5.570	.230	1.200	0.157-3.240	.859		
Systemic combined anomalies	15.500	4.500-42.90	<.001	43.200	10.30-181.0	<.001		

Abbreviations: OR, odds ratio; SGA, small for gestational age.

P values are shown in *italic* and significant differences are indicated in **bold**.

The purpose of the first statistical analysis was to exclude children whose delayed independent walking was not due to the pathogenesis of spinal lipoma. Forty-five percent of the subjects in this study exhibited some sort of malformation complication. To avoid the exclusion of all cases with malformation complications, complications were separated according to their severity. The study identified a delay in achieving independent walking in children with systemic combined anomalies, a finding that aligns with several existing reports.^{27,28} Simultaneously, associated anomalies such as anorectal or urogenital malformations appeared to be limited risk factors for delayed independent walking. This observation cannot be definitively confirmed due to the lack of relevant perspective reports. Given that congenital anomaly complications within spinal lipoma, stemming from neural tube defects, are relatively prevalent, the results of this study may be relevant to clinical practice.

Our subgroup analysis aimed to investigate factors within the pathogenesis of spinal lipomas associated with delayed independent walking. The findings indicated that a possible



Figure 3. Cumulative incidence of independent walking achievement according to congenital anomaly complications. Ninety percent of children in the groups with no remarkable anomalies and associated/minor malformations achieved independent walking by 15 months of age. However, in the systemic combined anomalies group, this achievement was observed in less than 25% of children by the same age milestone. The 90th percentile for the achievement of independent walking in the systemic combined anomalies group was more than 40 months (P < 0.001).

Table 3. Univariate and multivariate analyses of factors influencing the achievement of independent walking (excluding children with systemic combined anomalies).

DEPENDENT	INDEPENDENT VARIABLESª	UNIVARIATE ANALYSIS				MULTIVARIABLE ANALYSIS			
VARIABLES		COEFFICIENT	95%CI	95%CI		COEFFICIENT	95%CI		<i>P-</i>
		LOWER UPPE	UPPER	VALUE	LOWER		UPPER	VALUE	
Age of achievement	Sex, female=0, male=1	-0.117	-1.018	0.783	.796	-0.455	-1.413	0.502	.347
of independent walking	SGA	0.005	-0.906	0.915	.992				
(n=94)	Associated/minor malformations	0.389	-0.614	1.392	.443	0.515	-0.513	1.542	.322
	Extent of lipoma removal ^b	0.021	-0.879	0.921	.963	0.199	-0.713	1.111	.666
	Syrinx	-0.053	-0.954	0.848	.907	-0.285	-1.328	0.759	.589
	Low-set conus medullaris	0.171	-0.786	1.127	.724	-0.433	-1.713	0.846	.503
	Malformed conus medullaris	1.014	0.095	1.933	.031	1.431	0.300	2.562	.014
	Urinary management	1.296	0.339	2.254	.009				
	Defecation management	0.715	-0.223	1.653	.134				
	Foot symptoms	0.745	-0.142	1.631	.099				
	Toe symptoms	1.204	0.326	2.083	.008				
	Provision of foot orthoses	0.263	-0.693	1.218	.586				

Abbreviations: CI, confidence interval; SGA, small for gestational age.

^aThe values of these items were assigned binary scales of 0 or 1.

^bThe binary scale employs "1" to represent total removal and "0" to signify partial removal and conservative untethering.

P values are shown in *italic* and significant differences are indicated in **bold**.

Table 4. Comparison of lumbosacral lipoma patient characteristics based on Morota's classification types (excluding children with systemic combined anomalies).

	TYPE OF MOROTA'S CLASSIFICATION							
VARIABLES	TYPE 1	TYPE 2	TYPE 3	TYPE 4				
	N=14	N=21	N=12	N=47				
Sex, male	3 (21%)	12 (57%)	6 (50%)	24 (51%)	.253			
SGA	2 (14%) ^d	8 (38%)	6 (50%)	24 (51%)ª	.088			
Surgical procedures								
Age of untethering (months)	6.3 (2.1-155.0)	4.0 (0.1-8.3) ^{c,d}	7.7 (2.7-173.3) ^b	13.6 (3.4-139.9) ^b	<.001			
Untethered before independent walking	10 (71%)	21 (100%) ^d	9 (75%)	23 (49%) ^b	<.001			
Extent of lipoma removal								
Total removal	12 (86%) ^b	7 (33%) ^a	6 (50%)	22 (47%)	.020			
Partial removal	2 (14%) ^b	13 (62%) ^{a,d}	4 (33%)	9 (19%) ^ь	<.01			
Conservative untethering	0	1 (5%)	2 (17%)	16 (34%)	<.01			
MRI findings								
Syrinx	10 (71%)	14 (67%)	10 (83%) ^d	15 (32%)°	<.01			
Low-set conus medullaris	13 (93%) ^d	21 (100%) ^d	12 (100%) ^d	17 (36%) ^{a,b,c}	<.001			
Between L3 to L5	9 (64%)	12 (57%)	4 (33%)	12 (26%)	<.001			
Below S1	4 (29%)	9 (43%)	8 (67%)	5 (11%)	_			
Malformed conus medullaris	0 ^{b,c}	21 (100%) ^{a,d}	12 (100%)	0ь	<.001			
Lipomyelomeningocele, n (%)	0	13 (62%)	0	0	-			
Voiding management								
Urinary	1 (7%) ^b	13 (62%) ^{a,d}	4 (33%)	9 (19%) ^b	<.01			
Defecation	5 (36%)	10 (48%)	1 (8%)	16 (34%)	.144			
Motility/orthosis								
Foot symptoms	6 (43%)	17 (81%) ^d	7 (58%)	17 (36%) ^b	<.01			
Toe symptoms	7 (50%)	13 (62%) ^d	8 (67%)	11 (23%) ^b	<.01			
Orthotic device fabrications	5 (36%)	16 (76%) ^d	4 (33%)	6 (13%) ^b	<.001			
Independent walking (months)	13 (10-17)	14 (11-20)	13 (11-15)	13 (10-18)	.234			

Abbreviations: MRI, magnetic resonance imaging; SGA, small for gestational age.

Values represent the number of patients (%) or the median (range). Categorical variables were compared using Fisher's exact test.

Continuous variables were compared using the Kruskal-Wallis test.

Multiple comparisons were made using the Bonferroni method for categorical variables and Mann-Whitney test for continuous variables. Those significantly different from type 1 are indicated by "a," type 2 by "b," type 3 by "c," and type 4 by "d," respectively.

P values are shown in *italic* and significant differences are indicated in **bold**.

factor contributing to the delay was the presence of a malformed conus medullaris. This specific malformation is inherent in Morota types 2 and 3 according to their definitions.^{22,29} Notably, type 2 exhibited a delay in independent walking of approximately 1 month, while type 3 did not display such a

delay. These observations were comparable to the patterns seen in types 1 and 4. However, the analysis of cumulative incidence did not identify any significant delays (Figure 4). If the majority of cases had been operated on before independent walking achievement, there might have been a significant difference.




Figure 4. Cumulative incidence of achievement of independent walking stratified by Morota's classification types. Morota type 2 exhibited a delayed cumulative incidence in comparison to the other 3 types. However, the log-rank test did not reveal a significant difference (*P*=0.055).

The primary focus of consideration lies in determining whether the delayed independent walking in the screened children stemmed from a neurogenic motor deficit or not.

Most previous studies assessing neurogenic motor deficits have not focused on independent walking in infancy.5,12,13,30,31 In 1 study, Klain and Thompson³² reported that a patient who presented with mild neurological signs in infancy, without dysuria, achieved ambulation at 28 months without worsening neurological symptoms. In a different study, Vora et al³³ reported that neurological function was preserved in >90% of radical resections and that early surgical intervention prevented neurological deficits. In addition, Thompson et al³⁴ emphasized the need for cautious consideration of surgical treatment for Morota's classification type 1 and cases classified under the dorsal type of the Chapman and Arai classification without informed conus morphology. Collectively, these reports indicate that spinal lipomas over the conus medullaris represent significant risk factors and that appropriate untethering in infancy prevents and improves neurogenic motor deficits, contributing to the achievement of independent walking.

The potential impact of early untethering combined with partial lipoma removal might have been substantial in our Morota type 2 cases, where concerns about neurogenic motor deficits were prominent. This suggests that Morota type 2 cases inherently harbor pathogenic spinal lipoma malformations that contribute to neurogenic symptoms and pose a potential risk for unambiguous total removal. Interestingly, 81% of patients with type 2 also exhibited foot symptoms and motor deficit changes that warrant vigilant long-term observation. Meanwhile, in Morota type 3 cases, defined as the early phase of secondary neurulation failure, there existed a malformed conus medullaris located caudal to the spinal cord, accompanied by neurogenic lower limb deficits that occurred exclusively at the level of the sacral medullary nerve. Thus, it is reasonable to conclude that the presence of symptoms in the toes of 67% of patients with type 3 had minimal impact on the delay in achieving independent walking.

In this study, voiding management was associated with the achievement of independent walking (Table 3). Comparison according to Morota's classification demonstrated that more than 62% of type 2 patients required urinary management and up to 50% required defecation management in the mid-term period after untethering (Table 4). This incidence aligns with the reported outcomes in children with lipomyelomeningoceles by Vora et al³² and the surgical outcomes in children with lumbosacral lipomas by Vloo et al.⁵ Additionally, foot symptoms were present in three-fourths of Morota type 2 cases, and toe symptoms were present in two-thirds of type 2 and 3 cases. These symptoms are likely related to the involvement of the lumbosacral medullary nerve in the lipoma, supported by MRI findings showing malformed conus medullaris, lipomyelomeningoceles,35 or frequently, chaotic lipomas.¹² The delay in independent

walking in Morota type 2 could be attributed to a neurogenic cause, potentially necessitating urinary management as well. Further research is needed to investigate the relationship between delays in independent walking and other clinical features of lumbosacral lipomas.

Notably, our study also found that associated malformations, such as anorectal and/or urogenital malformations, did not strongly influence the delayed achievement of independent walking, whereas the presence of conus malformations did. Moreover, our findings underscore that the children with systemic combined anomalies experienced developmental delays in motor milestones, highlighting the importance of comprehensive rehabilitation.

Study limitations

The main limitation of the study is that it was retrospective: there were no descriptions of a unified assessment of neurogenic motor deficits, and it is uncertain whether the delay in independent walking was truly due to lower-limb dysfunction. Cognitive components may also be related to motor developmental delays. The timing of untethering surgery may also be a confounding factor in the study population, as there was a mix of patients who underwent surgery before or after independent walking. It is also worth mentioning that a considerable number of children with congenital anomaly complications underwent hospitalization for treatments during infancy. This could potentially contribute to delays in achieving motor developmental milestones. In addition, as this was a cross-sectional study, it was not feasible to explore the impact of the extent of lipoma removal and the symptomatic changes experienced before and after surgery. This underscores the need for future research in this area.

Conclusion

In 94 lumbosacral lipoma cases, excluding children with delayed independent walking due to systemic combined anomalies, it was suggested that the presence of malformed conus medullaris was associated with delayed achievement of independent walking.

This finding will contribute to the development of theoretical implications for these children and their guardians, and will encourage further research to explore the neural pathways linking malformations to motor deficits and assessing the impact of surgical interventions on motor outcomes.

This study thus lays the foundation for targeted interventions and refined rehabilitation approaches, enhancing both clinical practice and patient care.

Declarations

Ethical approval and consent to participate

This retrospective cohort study involving human participants was performed in accordance with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study was approved by the Ethics Committee of the ACHMC (approval number 2021093) and the Bioethics Committee of Nagoya University (approval number 22-501). As this was a study involving the secondary use of existing data, the requirement for individual consent was waived.

Consent for publication Not applicable.

Author contributions

Conceptualization: Chiaki Takeuchi, Shiro Sugiura, Remi Fujita, and Noriatsu Tatematsu; Data curation: Chiaki Takeuchi and Shiro Sugiura; Formal analysis: Chiaki Takeuchi, Shiro Sugiura, and Remi Fujita; Investigation: Chiaki Takeuchi and Shiro Sugiura; Methodology: Chiaki Takeuchi, Remi Fujita, and Noriatsu Tatematsu; Supervision: Shiro Sugiura and Hideshi Sugiura; Writing—original draft: Chiaki Takeuchi; Writing—review & editing: Chiaki Takeuchi, Shiro Sugiura, and Hideshi Sugiura.

Acknowledgements

We extend our gratitude to the pediatric neurosurgical team of the Aichi Children's Health and Medical Center for their valuable guidance in managing the medical records for our research activities. We also would like to thank Editage (www.editage. com) for English language editing.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

Competing interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Availability of data and materials

The datasets generated during and/or analyzed during the current study are not publicly available due to the ongoing nature of the relevant studies. However, they are available from the corresponding author upon reasonable request.

ORCID iD

Chiaki Takeuchi ២ https://orcid.org/0009-0008-0316-2642

REFERENCES

- Dias LS, Swaroop VT, de Angeli LRA, Larson JE, Rojas AM, Karakostas T. Myelomeningocele: a new functional classification. J Child Orthop. 2021;15:1-5.
- Hoffer MM, Feiwell E, Perry R, Perry J, Bonnett C. Functional ambulation in patients with myelomeningocele. J Bone Joint Surg Am. 1973;55:137-148.
- Silva T, Queiroz JR, Turcio KHL, et al. Effect of photo-biomodulation combined with physical therapy on functional performance in children with myelomeningocele: a protocol randomized clinical blind study. *PLoS One*. 2021;16:e0253963.

- Schoenmakers MA, de Groot JF, Gorter JW, Hillaert JL, Helders PJ, Takken T. Muscle strength, aerobic capacity and physical activity in independent ambulating children with lumbosacral spina bifida. *Disabil Rebabil*. 2009;31:259-266.
- De Vloo PD, Sharma J, Alderson L, et al. Radical resection of lumbosacral lipomas in children: the Great Ormond Street Hospital experience. *Childs Nerv Syst.* 2022;38:1113-1123.
- Thuy M, Chaseling R, Fowler A. Spinal cord detethering procedures in children: a 5 year retrospective cohort study of the early post-operative course. J Clin Neurosci. 2015;22:838-842.
- Koyanagi I, Iwasaki Y, Hida K, et al. Factors in neurological deterioration and role of surgical treatment in lumbosacral spinal lipoma. *Childs Nerv Syst.* 2000;16:143-149.
- 8. Blount JP, Elton S. Spinal lipomas. Neurosurg Focus. 2001;10:e3.
- Kang JK, Yoon KJ, Ha SS, Lee IW, Jeun SS, Kang SG. Surgical management and outcome of tethered cord syndrome in school-aged children, adolescents, and young adults. *J Korean Neurosurg Soc.* 2009;46:468-471.
- Khan F, Amatya B, Ng L, Galea M. Rehabilitation outcomes in persons with spina bifida: a randomized controlled trial. *J Rehabil Med.* 2015;47:734-740.
- 11. Lee JY, Kim KH, Park K, Wang KC. Retethering: a neurosurgical viewpoint. *J Korean Neurosurg Soc.* 2020;63:346-357.
- 12. Pang D. Surgical management of complex spinal cord lipomas: how, why, and when to operate. A review. *J Neurosurg Pediatr.* 2019;23:537-556.
- Pierre-Kahn A, Zerah M, Renier D, et al. Congenital lumbosacral lipomas. Childs Nerv Syst. 1997;13:298-334; discussion 335.
- Schoenmakers MA, Gooskens RH, Gulmans VA, et al. Long-term outcome of neurosurgical untethering on neurosegmental motor and ambulation levels. *Dev Med Child Neurol.* 2003;45:551-555.
- Shields LBE, Mutchnick IS, Peppas DS, Rosenberg E. Importance of physical examination and imaging in the detection of tethered cord syndrome. *Glob Pediatr Health.* 2019;6:2333794X19851419.
- Hepp ZS, Haas VM, Latal B, et al. Early childhood neurodevelopmental outcome after open prenatal spina bifida aperta repair. *Dev Med Child Neurol*. 2021;63:1302-1307.
- Takayanagi K, Iwasaki S, Yoshinaka Y. The role of the Maternal and Child Health Handbook system in reducing perinatal mortarity in Japan. *Clin Perform Qual Haelth Care.* 1993;1:29-33.
- Gould JF, Fuss BG, Roberts RM, Collins CT, Makrides M. Consequences of using chronological age versus corrected age when testing cognitive and motor development in infancy and intelligence quotient at school age for children born preterm. *PLoS One*. 2021;16:e0256824.
- WHO Multicentre Growth Reference Study Group. WHO Motor Development Study: windows of achievement for six gross motor development milestones. *Acta Paediatr Suppl.* 2006;450:86-95.

- Matsubara K, Hattori T, Narumi S. Achievement of developmental milestones recorded in real time: a mobile app-based study. *J Pediatr.* 2022;245:201-207.e9.
- Talge NM, Mudd LM, Sikorskii A, Basso O. United States birth weight reference corrected for implausible gestational age estimates. *Pediatrics*. 2014;133: 844-853.
- 22. Morota N, Ihara S, Ogiwara H. New classification of spinal lipomas based on embryonic stage. *J Neurosurg Pediatr.* 2017;19:428-439.
- Lim JX, Fong E, Goh C, Ng LP, Merchant K, Low DCY, et al. Fibrofatty filum terminale: longterm outcomes from a Singapore Children's Hospital. *J Neurosurg Pediatr.* 2023;31:197-205.
- Wang K, Yang L, Peng C, et al. Caudal duplication syndrome: 10-year experiences with as comprehensive literature review. *Pediatr Surg Int.* 2022;38: 1283-1289.
- Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. *Bone Marrow Transplant*. 2013;48:452-458.
- Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. *Behav Res Methods*. 2007;39:175-191.
- Okada S, Uejo T, Hirano R, et al. Assessing the efficacy of very early Motor rehabilitation in children with Down syndrome. *J Pediatr.* 2019;213: 227-231.e1.
- Uchio Y, Shima N, Nakamura K, Nitta O, Ikai T. Walking attainment in very low birth weight infants in Japan. *Phys Ther Res.* 2021;24:204-210.
- Tominey S, Kaliaperumal C, Gallo P. External vilification of a new classification of spinal lipomas based on embryonic stage. *J Neurosurg Pediatr.* 2020;25: 394-401.
- Kanev PM, Bierbrauer KS. Reflections on the natural history of lipomyelomeningocele. *Pediatr Neurosurg*. 1995;22:137-140.
- Sarris CE, Tomei KL, Carmel PW, Gandhi CD. Lipomyelomeningocele: pathology, treatment, and outcomes. *Neurosurg Focus*. 2012;33:E3.
- Klein O, Thompson D. Spontaneous regression of lipomyelomeningocele associated with terminal syringomyelia in a child. Case report. J Neurosurg. 2007;107:244-247.
- Vora TK, Girishan S, Moorthy RK, Rajshekhar V. Early- and long-term surgical outcomes in 109 children with lipomyelomeningocele. *Childs Nerv Syst.* 2021;37:1623-1632.
- Thompson DNP, Spoor J, Schotman M, Maestri S, Craven CL, Desai D. Does conus morphology have implications for outcome in lumbosacral lipoma? *Childs Nerv Syst.* 2021;37:2025-2031.
- McLone DG, Tompson DNP. Lipomas of the spine. In: McLone DG, ed. Pediatric Neurosurgery: Surgery of the Developing Nervous System. Saunders; 2001: 289-301.